Testing a new gene-editing treatment for high cholesterol

This trial is testing a new medication called VERVE-102, which uses gene-editing technology to help your liver produce less of a protein that raises cholesterol. The medication is designed for people with familial hypercholesterolemia or premature heart disease who need additional help lowering their cholesterol. This is an early-stage study to understand whether the treatment is safe and how well it works.

Many people with familial hypercholesterolemia or early heart disease struggle to get their cholesterol low enough with current medications alone. This medication represents a new approach using gene-editing to address the root cause, and researchers need to first confirm it is safe in patients.